The company expects to launch the nasal spray product in 2013.
National registration processes, including price and reimbursement, will now follow in each country, the company said.
Meda CEO Anders Lonner said the product has been launched in the US with good success.
"With the addition of Dymista (currently in registration phase) Meda will have an extraordinary strong position in the allergy rhinitis area, both in the US and Europe", Lonner added.